Skip to Content
Merck
  • Two High Throughput Screen Assays for Measurement of TNF-α in THP-1 Cells.

Two High Throughput Screen Assays for Measurement of TNF-α in THP-1 Cells.

Current chemical genomics (2011-06-07)
Kristin P Leister, Ruili Huang, Bonnie L Goodwin, Andrew Chen, Christopher P Austin, Menghang Xia
ABSTRACT

Tumor Necrosis Factor-α (TNF-α), a secreted cytokine, plays an important role in inflammatory diseases and immune disorders, and is a potential target for drug development. The traditional assays for detecting TNF-α, enzyme linked immunosorbent assay (ELISA) and radioimmunoassay, are not suitable for the large size compound screens. Both assays suffer from a complicated protocol, multiple plate wash steps and/or excessive radioactive waste. A simple and quick measurement of TNF-α production in a cell based assay is needed for high throughput screening to identify the lead compounds from the compound library. We have developed and optimized two homogeneous TNF-α assays using the HTRF (homogeneous time resolved fluorescence) and AlphaLISA assay formats. We have validated the HTRF based TNF-α assay in a 1536-well plate format by screening a library of 1280 pharmacologically active compounds. The active compounds identified from the screen were confirmed in the AlphaLISA TNF-α assay using a bead-based technology. These compounds were also confirmed in a traditional ELISA assay. From this study, several beta adrenergic agonists have been identified as TNF-α inhibitors. We also identified several novel inhibitors of TNF-α, such as BTO-1, CCG-2046, ellipticine, and PD 169316. The results demonstrated that both homogeneous TNF-α assays are robust and suitable for high throughput screening.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bay 11-7085, ≥98% (HPLC), solid
Sigma-Aldrich
IRAK-1/4 Inhibitor I, ≥98% (HPLC), solid
Sigma-Aldrich
BTO-1, ≥98% (HPLC), solid